Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: Results of cancer and leukemia group B trial 159806

Breast Cancer Research and Treatment

Volumn 100, Issue 3, 2006, Pages 301-308

  Rincon, Mercedes ^a   Broadwater, Gloria ^b   Harris, Lyndsay ^c   Crocker, Abigail ^a   Weaver, Donald ^a   Dressler, Lynn ^d   Berry, Donald ^b   Sutton, Linda ^e   Michaelson, Richard ^f   Messino, Michael ^g   Kirshner, Jeffrey ^h   Fleming, Gini ⁱ   Winer, Eric ^c   Hudis, Clifford ^j   Appel, Stacy ^a   Norton, Larry ^j   Muss, Hyman ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g Southeast Cancer Control Consortium Inc   (United States)

^h SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

Breast cancer; IL 6; Metastases; Paclitaxel response; PGP

Indexed keywords

GLYCOPROTEIN P; INTERLEUKIN 6; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAMPLE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-6; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; P-GLYCOPROTEIN; PACLITAXEL; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33750728891     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9251-7     Document Type: Article

References (23)

1. Miller KD, Sledge GW Jr (1999) Taxanes in the treatment of breast cancer: a prodigy comes of age. Cancer Invest 17:121-136
2. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S et al (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983
3. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439
4. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, et al (2001) Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61:8851-8858
5. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN et al (2004) Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22:2061-2068
6. Markowska J, Wiktorowicz K, Szewierski Z, Madry R (1995) The value of determining the interleukin-6 levels in epithelial ovarian cancer. Ann N Y Acad Sci. 762:446-449
7. Scambia G, Testa U, Panici PB, Martucci R, Foti E, Petrini M et al (1994) Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer 57:318-323
8. Scambia G, Testa U, Benedetti PP, Foti E, Martucci R, Gadducci A et al (1995) Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 71:354-356
9. Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T et al (1995) Serum levels of interleukin-6 in patients with lung cancer. Br J Cancer 71:1095-1098
10. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW (1995) Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45:542-549
11. Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ (2003) Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst 48:82-84
12. Kuang Y, Zhang Z, Zhang X (1998) Interleukin-6 and its soluble receptors in human breast cancer. Zhonghua Zhong Liu Za Zhi 20:305-307
13. Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY (2002) Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2:311-315
14. Niitsu N, Okamato M, Nakamine H, Yoshino T, Tamaru J, Nakamura S et al (2002) Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol 68:91-100
15. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E et al (2003) Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103:642-646
16. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW (2004) Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23:2934-2949
17. Bergman PJ (2003) Mechanisms of anticancer drug resistance. Vet Clin North Am Small Anim Pract 33:651-667
18. DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M et al (2003) Interleukin-6-174G → C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 63:8051-8056
19. Trock BJ, Leonessa F, Clarke R (1997) Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89:917-931
20. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58
21. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
22. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685
23. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL et al (2005) Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23:1169-1177